Open Government Portal
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products.
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products
The purpose of this Notice of Amendment is to notify about the additions of amifampridine, cedazuridine (when used in combination with another drug), etomidate, fedratinib, lefamulin, obiltoxaximab, polatuzumab vedotin, ripretinib, satralizumab and sonidegib to the Prescription Drug List (PDL) for human and/or veterinary use.
The purpose of this Notice of Amendment is to notify about the additions of fostamatinib, givosiran, lemborexant, luspatercept, ozanimod, trientine, and voretigene neparvovec to the Prescription Drug List (PDL) for human and veterinary use.
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products.
Provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products for health care professionals.
Provides clinically relevant safety information on pharmaceuticals, biologics, medical devices and natural health products for health care professionals.
This monthly publication is intended primarily for healthcare professionals and includes information on pharmaceuticals, biologics, medical devices and natural health products.